7. CBR, PFS and OS with or without deleterious gBRCA mutations according to type of chemotherapy .

Results	PBCT (n=44)				NPCT (n=70)
	With (n=7)	Without (n=37)	P		With (n=7)	Without (n=63)	P
CBR, clinical benefit rate; PFS, progression-free survival; OS, overall survival; gBRCA, germline BRCA1/2; PBCT, platinum-based chemotherapy; NPCT, non-platinum-based chemotherapy; 95% CI, 95% confidence interval.
CBR	85.7% (6/7)	35.1% (13/37)	0.039		57.1% (4/7)	39.7% (25/63)	0.627
PFS [median (95% CI)] (month)	14.9 (6.9−22.9)	5.3 (4.0−6.6)	0.001		5.8 (1.2−10.4)	5.1 (3.8−6.4)	0.677
OS [median (95% CI)] (month)	26.5 (−)	15.5 (10.9−20.2)	0.161		−	14.5 (10.4−18.6)	0.075